المؤلفون: Mathias Castonguay, Rola El Sayed, Corentin Richard, Marie-France Vachon, Rami Nassabein, Danielle Charpentier, Mustapha Tehfé

المصدر: Current Oncology, Vol 29, Iss 5, Pp 3282-3290 (2022)

مصطلحات موضوعية: COVID-19, colorectal cancer, cancer screening, diagnosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Background: Public health measures have imposed drastic reductions in cancer screening programs at the beginning of the COVID-19 pandemic, with an unknown impact on the diagnosis and staging of colorectal cancer (CRC). Methods: Newly diagnosed CRC cases at the Centre Hospitalier de l’Université de Montréal (CHUM) were divided into two groups according to the timeline: pre-pandemic (1 January 2018–12 March 2020), and pandemic (13 March 2020–30 June 2021) periods. Colonoscopy, surgery, and staging at diagnosis during the pandemic period were compared to the pre-pandemic period. Results: 254 CRC diagnoses were made during the pre-pandemic period in comparison to 125 during the pandemic period. Mean diagnosis rates were lower in the pandemic period (7.8 vs. 9.8 diagnoses/month, p = 0.048). Colonoscopy deadlines were less respected in the pandemic period (51.7% vs. 38.3%, p = 0.049). The rate of elective surgery did not differ (2.9 vs. 3.5 surgeries/month, p = 0.39) and mean delays were similar (58.6 vs. 60.4 days, p = 0.77). Stages at diagnosis did not differ (p = 0.17). Most of the delayed colonoscopies led to a stage 0 or I CRC (p = 0.2). Conclusion: In our center, the COVID-19 pandemic resulted in a decreased rate of CRC diagnosis and increased endoscopic delays without affecting the rate of advanced stage disease. Delays to surgery were quite similar once the CRC diagnosis was established.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1718-7729/29/5/268Test; https://doaj.org/toc/1198-0052Test; https://doaj.org/toc/1718-7729Test

الوصول الحر: https://doaj.org/article/56006c0e85f64cd1b2fa242adecdc9a0Test

المؤلفون: Francis Proulx-Rocray, Bertrand Routy, Rami Nassabein, Wiam Belkaid, Danh Tran-Thanh, Julie Malo, Marion Tonneau, Omar El Ouarzadi, Marie Florescu, Mustapha Tehfe, Normand Blais

المصدر: Cancer Treatment and Research Communications, Vol 37, Iss , Pp 100767- (2023)

مصطلحات موضوعية: NSCLC, Immunotherapy, KRAS, STK11, KEAP1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Background: PD-L1 expression is used to predict NSCLC response to ICIs, but its performance is suboptimal. The impact of KRAS mutations in these patients is unclear. Studies evaluating co-mutations in TP53, STK11 and KEAP1 as well as the NLR showed that they may predict the benefit of ICIs. Patients & methods: This is a retrospective study of patients with NSCLC treated with ICIs at the CHUM between July 2015 and June 2020. OS and PFS were compared using Kaplan-Meier and logrank methods. Co-mutations in TP53, STK11 and KEAP1 as well as the NLR were accounted for. ORR and safety were compared using Wald method. Results: From 100 patients with known KRAS status, 50 were mutated (KRASMut). Mutation in TP53, STK11 and KEAP1 were present, and their status known in, respectively, 19/40 (47.5 %), 8/39 (20.5 %) and 4/38 (10.5 %) patients. STK11Mut and KEAP1Mut were associated with shorter overall survival when compared with wild type tumors (respectively median OS of 3.3 vs 20.4, p = 0.0001 and 10.1 vs 17.7, p = 0.24). When KRAS status was compounded with STK11/KEAP1, KRASMut trended to a better prognosis in STK11+KEAP1WT tumors (median OS 21.1 vs 15.8 for KRASWT, p = 0.15), but not for STK11+/-KEAP1Mut tumors. The NLR was strongly impacted by STK11 (6.0Mut vs 3.6WT, p = 0.014) and TP53 (3.2Mut vs 4.8WT, p = 0.048), but not by KEAP1 or KRAS mutations. Conclusion: STK11Mut and KEAP1Mut are adverse predictors of ICI therapy benefit. The NLR is strongly impacted by STK11Mut but not by KEAP1Mut, suggesting differences in their resistance mechanism. In STK11-KEAP1WT tumors, KRASMut seem associated with improved survival in NSCLC patients treated with ICIs. MicroAbstract: Response of NSCLC to immunotherapy is not easily predictable. We conducted a retrospective study in 100 patients with NSCLC and a known KRAS status. By accounting for different co-mutations, KRAS mutation was found to be associated with a better median overall survival in STK11 and KEAP1 wild-type tumors (21.1 vs 15.8, p = 0.15). NLR was impacted by STK11, but not KEAP1 mutation, suggesting a difference in their resistance mechanism.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2468294223000898Test; https://doaj.org/toc/2468-2942Test

الوصول الحر: https://doaj.org/article/c40f1a47fa0642819660bfc828e84fc3Test

المؤلفون: Rami Nassabein, Laura Mansour, Corentin Richard, Franck Vandenbroucke-Menu, Francine Aubin, Jean-Pierre Ayoub, Michel Dagenais, Real Lapointe, Richard Letourneau, Marylène Plasse, André Roy, Simon Turcotte, Mustapha Tehfe

المصدر: Current Oncology, Vol 28, Iss 3, Pp 1899-1908 (2021)

مصطلحات موضوعية: colon cancer, CRLM, hepatic metastectomy, perioperative chemotherapy, NLR, comprehensive geriatric assessment, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Surgery is the only potential curative option of CRLM if resectable. The curative approach in patients over 70 years old is challenging mainly because of comorbidities and other geriatric syndromes. Herein, we report outcomes of older patients with resectable CRLM in our center. We retrospectively analyzed characteristics and outcomes of older patients with CRLM operated at “Centre Hospitalier de l’Université de Montréal” (CHUM) between 2010 and 2019. We identified 210 patients aged ≥70 years with a median age of 76 (range: 70–85). CRLM were synchronous in 56% of patients. Median disease-free survival (DFS) was 41.3 months. Median overall survival (OS) was 62.2 months and estimated 5-year survival rate was 51.5% similar to those of younger counterparts. Patients with metachronous CRLM had a trend to a higher OS compared to those with synchronous disease (67.2 vs. 58.7 months; p = 0.42). Factors associated with lower survival in the multivariate analysis were right-sided tumors and increased Charlson Comorbidity index (CCI). Survival outcomes of patients aged ≥70 years were comparable to those of younger patients and those reported in the literature. Age should not be a limiting factor in the curative management of older patients with resectable CRLM.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1718-7729/28/3/176Test; https://doaj.org/toc/1198-0052Test; https://doaj.org/toc/1718-7729Test

الوصول الحر: https://doaj.org/article/37755ca381d84838ac873ea2be6e2111Test

المؤلفون: Joanna Gotfrit, Rachel Goodwin, Timothy Asmis, Angela J. Hyde, Thierry Alcindor, Francine Aubin, Scott Berry, Dominick Bossé, Colin Brown, Ronald Burkes, Margot Burnell, Bruce Colwell, Jessica Corbett, Jeff Craswell, Nathalie Daaboul, Mark Doherty, D. A. Barry Fleming, Luisa Galvis, Rakesh Goel, Mohammed Harb, Alwin Jeyakumar, Derek Jonker, Erin Kennedy, Michael Lock, Aamer Mahmud, Patrick H. McCrea, Vimoj Nair, Rami Nassabein, Carolyn Nessim, Ravi Ramjeesingh, Muhammad Raza, Wissam Saliba, Satareh Samimi, Simron Singh, Stephanie Snow, Mustapha Tehfé, Michael Thirlwell, Mario Valdes, Stephen Welch, Michael Vickers

المصدر: Current Oncology, Vol 28, Iss 3, Pp 1988-2006 (2021)

مصطلحات موضوعية: guidelines, anal cancer, biliary tract cancer, colon cancer, gastric cancer, rectal cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019 was held in Morell, Prince Edward Island, 19–21 September 2019. Experts in medical oncology, radiation oncology, and surgical oncology who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of anal, colorectal, biliary tract, and gastric cancers, including: radiotherapy and systemic therapy for localized and advanced anal cancer; watch and wait strategy for the management of rectal cancer; role of testing for dihydropyrimidine dehydrogenase (DPD) deficiency prior to commencement of fluoropyrimidine therapy; radiotherapy and systemic therapy in the adjuvant and unresectable settings for biliary tract cancer; and radiotherapy and systemic therapy in the perioperative setting for early-stage gastric cancer.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1718-7729/28/3/185Test; https://doaj.org/toc/1198-0052Test; https://doaj.org/toc/1718-7729Test

الوصول الحر: https://doaj.org/article/4fa09d7c1ccc49218dd9a019789f6534Test

المؤلفون: Shamini Selvarajah, PhD, Sophie Plante, MSc, Marsha Speevak, PhD, Andrea Vaags, PhD, Darren Hamelinck, MSc, Martin Butcher, MSc, Elizabeth McCready, PhD, Daria Grafodatskaya, PhD, Normand Blais, MD, Danh Tran-Thanh, MD, Xiaoduan Weng, MD, Rami Nassabein, MD, Wenda Greer, PhD, Ryan N. Walton, MPH, Bryan Lo, MD, Doug Demetrick, MD, Stephanie Santos, BSc, Bekim Sadikovic, PhD, Xiao Zhang, BSc, MSc, Tong Zhang, MD, Tara Spence, PhD, Tracy Stockley, PhD, Harriet Feilotter, PhD, Philippe Joubert, MD, PhD

المصدر: JTO Clinical and Research Reports, Vol 2, Iss 8, Pp 100212- (2021)

مصطلحات موضوعية: Non–small cell lung cancer, Plasma ctDNA testing, Liquid biopsy, EGFR T790M variant, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Introduction: Genotyping circulating tumor DNA (ctDNA) is a promising noninvasive clinical tool to identify the EGFR T790M resistance mutation in patients with advanced NSCLC with resistance to EGFR inhibitors. To facilitate standardization and clinical adoption of ctDNA testing across Canada, we developed a 2-phase multicenter study to standardize T790M mutation detection using plasma ctDNA testing. Methods: In phase 1, commercial reference standards were distributed to participating clinical laboratories, to use their existing platforms for mutation detection. Baseline performance characteristics were established using known and blinded engineered plasma samples spiked with predetermined concentrations of T790M, L858R, and exon 19 deletion variants. In phase II, peripheral blood collected from local patients with known EGFR activating mutations and progressing on treatment were assayed for the presence of EGFR variants and concordance with a clinically validated test at the reference laboratory. Results: All laboratories in phase 1 detected the variants at 0.5 % and 5.0 % allele frequencies, with no false positives. In phase 2, the concordance with the reference laboratory for detection of both the primary and resistance mutation was high, with next-generation sequencing and droplet digital polymerase chain reaction exhibiting the best overall concordance. Data also suggested that the ability to detect mutations at clinically relevant limits of detection is generally not platform-specific, but rather impacted by laboratory-specific practices. Conclusions: Discrepancies among sending laboratories using the same assay suggest that laboratory-specific practices may impact performance. In addition, a negative or inconclusive ctDNA test should be followed by tumor testing when possible.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2666364321000710Test; https://doaj.org/toc/2666-3643Test

الوصول الحر: https://doaj.org/article/4343799e3fbf40999e9a88df77f2790eTest

المؤلفون: Rami Nassabein, Pierre-Olivier Gaudreau, Wiam Belkaid, Marie Florescu, Normand Blais

المصدر: Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100421- (2021)

مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2468294221001192Test; https://doaj.org/toc/2468-2942Test

الوصول الحر: https://doaj.org/article/b2d65e60d9e44ef1a790009b2780cfa1Test

المؤلفون: Scott R. Berry, Stephanie Snow, Alwin Jeyakumar, Ravi Ramjeesingh, Carolyn Nessim, Timothy R. Asmis, Patrick H McCrea, Jeff Craswell, Satareh Samimi, Mark Doherty, Mario Valdes, Jessica Corbett, Rachel Anne Goodwin, M. Vickers, Dominick Bossé, Thierry Alcindor, Francine Aubin, Erin D. Kennedy, Aamer Mahmud, Angela J Hyde, Michael Lock, Rami Nassabein, Margot J. Burnell, Simron Singh, Wissam Saliba, Derek J. Jonker, Mustapha Tehfe, Luisa Galvis, M. Thirlwell, Rakesh Goel, Vimoj Nair, Mohammed Harb, Ronald Burkes, Colin Brown, Muhammad Asim Raza, Joanna Gotfrit, Nathalie Daaboul, D A Barry Fleming, Stephen Welch, B. Colwell

المصدر: Current Oncology, Vol 28, Iss 185, Pp 1988-2006 (2021)
Current Oncology

مصطلحات موضوعية: medicine.medical_specialty, anal cancer, Colorectal cancer, medicine.medical_treatment, chemotherapy, radiation therapy, Systemic therapy, surgery, Surgical oncology, biliary tract cancer, medicine, Anal cancer, guidelines, Gastrointestinal cancer, rectal cancer, RC254-282, business.industry, gastric cancer, General surgery, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cancer, Conference Report, Perioperative, medicine.disease, Radiation therapy, colon cancer, business

الوصف: The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019 was held in Morell, Prince Edward Island, 19–21 September 2019. Experts in medical oncology, radiation oncology, and surgical oncology who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of anal, colorectal, biliary tract, and gastric cancers, including: radiotherapy and systemic therapy for localized and advanced anal cancer; watch and wait strategy for the management of rectal cancer; role of testing for dihydropyrimidine dehydrogenase (DPD) deficiency prior to commencement of fluoropyrimidine therapy; radiotherapy and systemic therapy in the adjuvant and unresectable settings for biliary tract cancer; and radiotherapy and systemic therapy in the perioperative setting for early-stage gastric cancer.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aeaef477e95e74ec19b16880da4fffaTest
https://doi.org/10.3390/curroncol28030185Test

المؤلفون: Franck Vandenbroucke-Menu, Réal Lapointe, Michel Dagenais, Marylène Plasse, Francine Aubin, Laura Mansour, Rami Nassabein, André Roy, Jean-Pierre M. Ayoub, Simon Turcotte, Corentin Richard, Richard Letourneau, Mustapha Tehfe

المصدر: Current Oncology
Current Oncology, Vol 28, Iss 176, Pp 1899-1908 (2021)
Volume 28
Issue 3
Pages 176-1908

مصطلحات موضوعية: medicine.medical_specialty, Multivariate analysis, Colorectal cancer, CRLM, Disease, Single Center, Disease-Free Survival, Article, NLR, 03 medical and health sciences, 0302 clinical medicine, Older patients, Internal medicine, Hepatectomy, Humans, Medicine, Survival rate, RC254-282, Aged, Retrospective Studies, hepatic metastectomy, business.industry, Liver Neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cancer, comprehensive geriatric assessment, medicine.disease, colon cancer, perioperative chemotherapy, 030220 oncology & carcinogenesis, Charlson comorbidity index, 030211 gastroenterology & hepatology, Colorectal Neoplasms, business

الوصف: Surgery is the only potential curative option of CRLM if resectable. The curative approach in patients over 70 years old is challenging mainly because of comorbidities and other geriatric syndromes. Herein, we report outcomes of older patients with resectable CRLM in our center. We retrospectively analyzed characteristics and outcomes of older patients with CRLM operated at “Centre Hospitalier de l’Université de Montréal” (CHUM) between 2010 and 2019. We identified 210 patients aged ≥70 years with a median age of 76 (range: 70–85). CRLM were synchronous in 56% of patients. Median disease-free survival (DFS) was 41.3 months. Median overall survival (OS) was 62.2 months and estimated 5-year survival rate was 51.5% similar to those of younger counterparts. Patients with metachronous CRLM had a trend to a higher OS compared to those with synchronous disease (67.2 vs. 58.7 months
p = 0.42). Factors associated with lower survival in the multivariate analysis were right-sided tumors and increased Charlson Comorbidity index (CCI). Survival outcomes of patients aged ≥70 years were comparable to those of younger patients and those reported in the literature. Age should not be a limiting factor in the curative management of older patients with resectable CRLM.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42f1b16894c0a965167e84ddf783154bTest
https://doi.org/10.3390/curroncol28030176Test

المؤلفون: Frederic Lemay, Xiaoduan Weng, Normand Blais, Rami Nassabein, Jean-Pierre M. Ayoub, Anne-Sophie Lemay, Christian Carrier, Rasmy Loungnarath, Patrice Beauregard, Francois Letendre, Daniel Viens, Francine Aubin, Alexis-Simon Cloutier, Charles Vadnais, Alexandra Desnoyers, Mustapha Tehfe, Denis Soulières, Catherine Jolivet, Carl Amireault, Jacques Jolivet

المصدر: Oncologist

مصطلحات موضوعية: 0301 basic medicine, Antimetabolites, Antineoplastic, Canada, Cancer Research, medicine.medical_specialty, Cancer Diagnostics and Molecular Pathology, Genotype, medicine.medical_treatment, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Mucositis, Humans, Genotyping, Dihydrouracil Dehydrogenase (NADP), Retrospective Studies, Chemotherapy, business.industry, Quebec, medicine.disease, Rash, Diarrhea, 030104 developmental biology, Oncology, Fluorouracil, 030220 oncology & carcinogenesis, DPYD, medicine.symptom, business, medicine.drug

الوصف: Background Fluoropyrimidines are used in chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. DPYD*2A polymorphism is one of the most studied variants. The study objective was to document the impact of implementing this test in routine clinical practice. Methods We retrospectively performed chart reviews of all patients who tested positive for a heterozygous or homozygous DPYD*2A mutation in samples obtained from patients throughout the province of Quebec, Canada. Results During a period of 17 months, 2,617 patients were tested: 25 patients tested positive. All were White. Twenty-four of the 25 patients were heterozygous (0.92%), and one was homozygous (0.038%). Data were available for 20 patients: 15 were tested upfront, whereas five were identified after severe toxicities. Of the five patients confirmed after toxicities, all had grade 4 cytopenias, 80% grade ≥3 mucositis, 20% grade 3 rash, and 20% grade 3 diarrhea. Eight patients identified with DPYD*2A mutation prior to treatment received fluoropyrimidine-based chemotherapy at reduced initial doses. The average fluoropyrimidine dose intensity during chemotherapy was 50%. No grade ≥3 toxicities were observed. DPYD*2A test results were available in an average of 6 days, causing no significant delays in treatment initiation. Conclusion Upfront genotyping before fluoropyrimidine-based treatment is feasible in clinical practice and can prevent severe toxicities and hospitalizations without delaying treatment initiation. The administration of chemotherapy at reduced doses appears to be safe in patients heterozygous for DPYD*2A. Implications for Practice Fluoropyrimidines are part of chemotherapy combinations for multiple cancers. Deficient dihydropyrimidine dehydrogenase activity can lead to severe life-threatening toxicities. This retrospective analysis demonstrates that upfront genotyping of DPYD before fluoropyrimidine-based treatment is feasible in clinical practice and can prevent severe toxicities and hospitalizations without delaying treatment initiation. This approach was reported previously, but insufficient data concerning its application in real practice are available. This is likely the first reported experience of systematic DPYD genotyping all over Canada and North America as well.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0a671cf8bc2d5f485811656a2c42204Test
https://doi.org/10.1002/onco.13626Test

المؤلفون: Wenda L. Greer, Normand Blais, Danh Tran-Thanh, Rami Nassabein, Tracy Stockley, Tara Spence, Martin Butcher, R. Walton, Stephanie Santos, Xiao Zhang, Doug Demetrick, Shamini Selvarajah, Bryan Lo, Bekim Sadikovic, Marsha Speevak, Sophie Plante, Andrea K. Vaags, Elizabeth McCready, Darren Hamelinck, Tong Zhang, Daria Grafodatskaya, Philippe Joubert, Harriet Feilotter, Xiaoduan Weng

المصدر: JTO Clinical and Research Reports, Vol 2, Iss 8, Pp 100212-(2021)
Paediatrics Publications

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Liquid biopsy, business.industry, Plasma ctDNA testing, Concordance, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Resistance mutation, T790M, EGFR T790M variant, Internal medicine, medicine, Non–small cell lung cancer, Digital polymerase chain reaction, business, Genotyping, Allele frequency, RC254-282, EGFR inhibitors

الوصف: Introduction Genotyping circulating tumor DNA (ctDNA) is a promising noninvasive clinical tool to identify the EGFR T790M resistance mutation in patients with advanced NSCLC with resistance to EGFR inhibitors. To facilitate standardization and clinical adoption of ctDNA testing across Canada, we developed a 2-phase multicenter study to standardize T790M mutation detection using plasma ctDNA testing. Methods In phase 1, commercial reference standards were distributed to participating clinical laboratories, to use their existing platforms for mutation detection. Baseline performance characteristics were established using known and blinded engineered plasma samples spiked with predetermined concentrations of T790M, L858R, and exon 19 deletion variants. In phase II, peripheral blood collected from local patients with known EGFR activating mutations and progressing on treatment were assayed for the presence of EGFR variants and concordance with a clinically validated test at the reference laboratory. Results All laboratories in phase 1 detected the variants at 0.5 % and 5.0 % allele frequencies, with no false positives. In phase 2, the concordance with the reference laboratory for detection of both the primary and resistance mutation was high, with next-generation sequencing and droplet digital polymerase chain reaction exhibiting the best overall concordance. Data also suggested that the ability to detect mutations at clinically relevant limits of detection is generally not platform-specific, but rather impacted by laboratory-specific practices. Conclusions Discrepancies among sending laboratories using the same assay suggest that laboratory-specific practices may impact performance. In addition, a negative or inconclusive ctDNA test should be followed by tumor testing when possible.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a822a1f06d5c0b5f9e1183019fb983bTest
http://www.sciencedirect.com/science/article/pii/S2666364321000710Test